In addition, the role of sGC stimulants in improving cGMP signaling might enable them to play an active role in a wide range of clinical indications, such as metabolic diseases, fibrotic diseases, urinary diseases, and neurodegenerative diseases. This evidence concerns the gene SGCB and neurodegenerative disease.